Mouse Anti-Human TIE-2
Slide this table
| Cat-Nr. | 101-M54 |
| Size | 100 µg |
| Price | 240 € |
| Category | Monoclonal Antibody |
| Clone Nr. | (#tek16) |
| Isotype | IgG1 |
| Species Reactivity | Human |
| Formulation | lyophilized |
| Buffer | PBS |
| Reconstitution | Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml. |
| Stability and Storage | The lyophilized antibody is stable for at least 2 years at -20°C. After sterile reconstitution the antibody is stable at 2-8°C for up to 6 months. Frozen aliquots are stable for at least 6 months when stored at -20°C. Addition of a carrier protein or 50% glycerol is recommended for frozen aliquots. |
| Preparation | The monoclonal antibody was produced with the help of BALB/c mice using recombinant human soluble extracellular TIE-2 as the immunizing antigen. Mouse IgG1 antibody (#tek16) from hybridomas was purified from cell culture supernatant by Protein G chromatography. |
| Antigen | recombinant human soluble extracellular TIE-2 |
| Application | ELISA, WB, FC |
| Synonyms | TEK; TIE2; VMCM; TIE-2; VMCM1; CD202B |
| Description | Tie-1/Tie and Tie-2/Tek are receptor tyrosine kinases with unique structural characteristics including two immunoglobulin-like domains flanking three epidermal growth factor (EGF)-like domains, followed by three fibronectin type III-like repeats in the extracellular region, and a split tyrosine kinase domain in the cytoplasmic region. Tie-2 is involved in vascular stabilization and remodeling. Although less well understood, Tie-1 may also act as an ANG receptor, possibly in complex with Tie-2. Human Tie-2 cDNA encodes a 1124 amino acid (aa) residue precursor protein with an 18 residue putative signal peptide, a 727 residue extracellular domain and a 354 residue cytoplasmic domain. Tie-2 is a receptor for the angiopoietin (ANG) family: ANG-1, ANG-2, and ANG-3 (mouse)/-4 (human). Ang-2 has been reported to act as an antagonist for Ang-1. Mice engineered to overexpress Ang-2 or to lack Ang-1 or Tie-2 display similar angiogenesis defects. |
| Uniprot ID | Q02763 |
| Protein RefSeq | NP_000450.2 |
| mRNA RefSeq | NM_000459.3 |
Figures
IHC with cryo sections of human spleen.
The experiment was performed by Prof. Dr. Birte Steiniger, Institute of Anatomy and Cell Biology Robert-Koch-Str. 8, D-35037 Marburg, Germany
Quantification of soluble and cellular TIE-2 by sandwich ELISA.
CM and cell lysates from HUVECs treated with PMA (25ng/ml) or left untreated were analysed by Sandwich ELISA for the concentrations of sTIE-2 or TIE-2. For capturing anti-human TIE-2 Cl.16 [#101-M54] was used, for the detection a mixture of biotinylated anti-human TIE-2 Cl.2 [#101-M50] and Cl.9 [#101-M52].
Effects of PMA treatment on TIE-2.
HUVECs (passage 1) were stimulated for the indicated periods of time with PMA at 25 ng/ml or left untreated. Western blot analysis for the presence of TIE-2 protein by immunoprecipitation using antibodies directed against the extracellular domain of human TIE-2 (IP: TEK16 [#101-M54]; Western: TEK2 [#101-M50]).
FACS analysis with human primary lymphatic endothelial cells (HDLEC). As secondary antibody anti-mouse IgG-PE was used.
Reference
- Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. Shahani T. et al., J Thromb Haemost. 2014 Jan;12(1):36-42.
- Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas. S. Norgall et al., BMC Cancer. 2007; 7: 105.
- Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood. Reusch P. et al., Angiogenesis. 2001;4(2):123-31.
- Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Harris AL et al., Clin Cancer Res. 2001 Jul;7(7):1992-7.
All prices plus VAT + possible delivery charges